May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Inhibition of Experimental Angiogenesis of Cornea by Bevacizumab
Author Affiliations & Notes
  • M. Ren
    Ophthalmology, Tulane, New Orleans, LA
  • R.P. A. Manzano
    Ophthalmology, Tulane, New Orleans, LA
  • G.A. Peyman
    Ophthalmology, Tulane, New Orleans, LA
  • P. Khan
    Ophthalmology, Tulane, New Orleans, LA
  • P. Carvounis
    Ophthalmology, Baylor, Houston, TX
  • M. Kivilcim
    Ophthalmology, Tulane, New Orleans, LA
  • Footnotes
    Commercial Relationships  M. Ren, None; R.P.A. Manzano, None; G.A. Peyman, None; P. Khan, None; P. Carvounis, None; M. Kivilcim, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 1638. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Ren, R.P. A. Manzano, G.A. Peyman, P. Khan, P. Carvounis, M. Kivilcim; Inhibition of Experimental Angiogenesis of Cornea by Bevacizumab . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1638.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the effect of topically administered bevacizumab (Avastin) on experimental corneal neovascularization in rats.

Methods: : Silver nitrate sticks (75% silver nitrate, 25% potassium nitrate) was used to perform chemical cauterization of the cornea of 16 eyes of 16 male Long–Evans (LE) rats. For the following 7 days, the 10 eyes in the treatment group received twice daily instillation of Bevacizumab 4mg/ml drops while the 6 eyes in the control group received placebo (normal saline drops twice daily). Digital photographs of the cornea were analyzed to determine the area of cornea covered by neovascularization as a percentage of the total corneal area.

Results: : In the Bevacizumab treated eyes, neovascularization covered, on average, 38.2 ± 15.5% (mean ± standard deviation[SD]) of the corneal surface compared with 63.5 ± 5.0% (mean ± SD) in the control group (p=0.0005, Student’s t–test).

Conclusions: : Topically administered Bevacizumab (Avastin) at a concentration of 4mg/ml limits corneal neovascularization following chemical injury in the male Long–Evans rat model.

Keywords: cornea: basic science • neovascularization 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.